Literature DB >> 33903906

Adjuvant therapy for high-risk medulloblastoma: more is better?

Douglas Strother1, Lucie Lafay-Cousin1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33903906      PMCID： PMC8248838          DOI： 10.1093/neuonc/noab104

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  7 in total

1.  Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study.

Authors:  Regina I Jakacki; Peter C Burger; Tianni Zhou; Emiko J Holmes; Mehmet Kocak; Arzu Onar; Joel Goldwein; Minesh Mehta; Roger J Packer; Nancy Tarbell; Charles Fitz; Gilbert Vezina; Joanne Hilden; Ian F Pollack
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

Authors:  Roger J Packer; Amar Gajjar; Gilbert Vezina; Lucy Rorke-Adams; Peter C Burger; Patricia L Robertson; Lisa Bayer; Deborah LaFond; Bernadine R Donahue; MaryAnne H Marymont; Karin Muraszko; James Langston; Richard Sposto
Journal:  J Clin Oncol       Date:  2006-09-01       Impact factor: 44.544

3.  Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).

Authors:  Amar Gajjar; Giles W Robinson; Kyle S Smith; Tong Lin; Thomas E Merchant; Murali Chintagumpala; Anita Mahajan; Jack Su; Eric Bouffet; Ute Bartels; Tal Schechter; Tim Hassall; Thomas Robertson; Wayne Nicholls; Sridharan Gururangan; Kristin Schroeder; Michael Sullivan; Greg Wheeler; Jordan R Hansford; Stewart J Kellie; Geoffrey McCowage; Richard Cohn; Michael J Fisher; Matthew J Krasin; Clinton F Stewart; Alberto Broniscer; Ivo Buchhalter; Ruth G Tatevossian; Brent A Orr; Geoff Neale; Paul Klimo; Frederick Boop; Ashok Srinivasan; Stefan M Pfister; Richard J Gilbertson; Arzu Onar-Thomas; David W Ellison; Paul A Northcott
Journal:  J Clin Oncol       Date:  2021-01-06       Impact factor: 44.544

4.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.

Authors:  Amar Gajjar; Murali Chintagumpala; David Ashley; Stewart Kellie; Larry E Kun; Thomas E Merchant; Shaio Woo; Greg Wheeler; Valerie Ahern; Matthew J Krasin; Maryam Fouladi; Alberto Broniscer; Robert Krance; Gregory A Hale; Clinton F Stewart; Robert Dauser; Robert A Sanford; Christine Fuller; Ching Lau; James M Boyett; Dana Wallace; Richard J Gilbertson
Journal:  Lancet Oncol       Date:  2006-10       Impact factor: 41.316

5.  Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.

Authors:  André O von Bueren; Rolf-Dieter Kortmann; Katja von Hoff; Carsten Friedrich; Martin Mynarek; Klaus Müller; Tobias Goschzik; Anja Zur Mühlen; Nicolas Gerber; Monika Warmuth-Metz; Niels Soerensen; Frank Deinlein; Martin Benesch; Isabella Zwiener; Robert Kwiecien; Andreas Faldum; Udo Bode; Gudrun Fleischhack; Volker Hovestadt; Marcel Kool; David Jones; Paul Northcott; Joachim Kuehl; Stefan Pfister; Torsten Pietsch; Stefan Rutkowski
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

6.  Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma.

Authors:  Lorenza Gandola; Maura Massimino; Graziella Cefalo; Carlo Solero; Filippo Spreafico; Emilia Pecori; Daria Riva; Paola Collini; Emanuele Pignoli; Felice Giangaspero; Roberto Luksch; Serena Berretta; Geraldina Poggi; Veronica Biassoni; Andrea Ferrari; Bianca Pollo; Claudio Favre; Iacopo Sardi; Monica Terenziani; Franca Fossati-Bellani
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5.

Authors:  Christelle Dufour; Stephanie Foulon; Anne Geoffray; Julien Masliah-Planchon; Dominique Figarella-Branger; Valerie Bernier-Chastagner; Laetitia Padovani; Léa Guerrini-Rousseau; Cecile Faure-Conter; Celine Icher; Anne-Isabelle Bertozzi; Pierre Leblond; Tasnime Akbaraly; Franck Bourdeaut; Nicolas André; Celine Chappé; Pascale Schneider; Emilie De Carli; Pascal Chastagner; Claire Berger; Julien Lejeune; Christine Soler; Natacha Entz-Werlé; Marie-Bernadette Delisle
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300
  7 in total
  2 in total

Review 1.  Role of Circular RNA in Brain Tumor Development.

Authors:  Swalih P Ahmed; Javier S Castresana; Mehdi H Shahi
Journal:  Cells       Date:  2022-07-06       Impact factor: 7.666

Review 2.  Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment.

Authors:  Sutapa Ray; Nagendra K Chaturvedi; Kishor K Bhakat; Angie Rizzino; Sidharth Mahapatra
Journal:  Diagnostics (Basel)       Date:  2021-12-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.